Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jonathan A. Fletcher, M.D.

Title
Institution
Department
Address
Phone
Fax
Other Positions
Title
Institution
Department

Mentoring
Available: 10/17/18, Expires: 10/16/22

Our lab translates advances in cancer biology into effective targeted therapies for adult and pediatric sarcomas. Current priorities include: 1) rational combination therapies; 2) new strategies for targeting oncogenic tyrosine kinases and the dysregulated cell cycle; 3) maximizing therapeutic response by targeting mechanisms of genetic/biologic progression in sarcomas. The student can participate in designing clinical trials of drugs validated in the laboratory studies. We lead several international research consortia in these fields, leading to rich collaborations and interactions.

Characterizing Dystrophin as a Prognostic Biomarker in Surgically-resected GIST
Summer, 04/01/13 - 08/19/13

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. P50CA127003 (BASS, ADAM JOEL) Apr 1, 2007 - May 31, 2024
    NIH/NCI
    SPORE: DF/HCC SPORE in GASTROINTESTINAL CANCER
    Role: Co-Principal Investigator
  2. R01CA072791 (FLETCHER, JONATHAN A) Sep 19, 1997 - Aug 31, 2000
    NIH/NCI
    TRANSLOCATION OF 8-13 IN STEM-CELL LEUKEMIA/LYMPHOMA
    Role: Principal Investigator
  3. R01CA068376 (FLETCHER, JONATHAN A) Apr 5, 1996 - Mar 31, 1999
    NIH/NCI
    TUMOR SUPPRESSOR LOCI IN MESOTHELIOMA
    Role: Principal Investigator
  4. P01CA068484 (SALLAN, STEPHEN E) Sep 30, 1995 - Apr 30, 2013
    NIH/NCI
    Therapeutic Index of Acute Lymphoblastic Leukemia
    Role: Co-Principal Investigator
  5. P20NS031110 (BLACK, PETER M) Sep 30, 1992 - Jun 30, 1996
    NIH/NINDS
    CHARACTERIZING AND INHIBITING ASTROCYTOMA GROWTH
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Serrano C, Vivancos A, López-Pousa A, Matito J, Mancuso FM, Valverde C, Quiroga S, Landolfi S, Castro S, Dopazo C, Sebio A, Virgili AC, Menso MM, Martín-Broto J, Sansó M, García-Valverde A, Rosell J, Fletcher JA, George S, Carles J, Arribas J. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. BMC Cancer. 2020 Feb 05; 20(1):99. PMID: 32024476.
    Citations:    
  2. Huang M, Yang W, Zhu J, Mariño-Enríquez A, Zhu C, Chen J, Wu Y, Quan Y, Qiu H, Li X, Chai L, Fletcher JA, Ou WB. Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours. Br J Cancer. 2020 Feb; 122(3):372-381. PMID: 31776458.
    Citations:    
  3. Serrano C, Fletcher JA. Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor. Oncotarget. 2019 Oct 29; 10(59):6286-6287. PMID: 31695836.
    Citations:    
  4. Pang Y, Xie F, Cao H, Wang C, Zhu M, Liu X, Lu X, Huang T, Shen Y, Li K, Jia X, Li Z, Zheng X, Wang S, He Y, Wang L, Fletcher JA, Wang Y. Mutational inactivation of mTORC1 repressor gene DEPDC5 in human gastrointestinal stromal tumors. Proc Natl Acad Sci U S A. 2019 Nov 05; 116(45):22746-22753. PMID: 31636198.
    Citations:    
  5. Serrano C, Leal A, Kuang Y, Morgan JA, Barysauskas CM, Phallen J, Triplett O, Mariño-Enríquez A, Wagner AJ, Demetri GD, Velculescu VE, Paweletz CP, Fletcher JA, George S. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Clin Cancer Res. 2019 Dec 15; 25(24):7287-7293. PMID: 31471313.
    Citations:    
  6. Ou WB, Ni N, Zuo R, Zhuang W, Zhu M, Kyriazoglou A, Wu D, Eilers G, Demetri GD, Qiu H, Li B, Marino-Enriquez A, Fletcher JA. Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence. Oncogene. 2019 09; 38(39):6615-6629. PMID: 31371779.
    Citations:    
  7. Hsueh YS, Chang HH, Shan YS, Sun HS, Fletcher JA, Li CF, Chen LT. Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors. Oncogene. 2019 09; 38(38):6550-6565. PMID: 31363162.
    Citations:    
  8. Mühlenberg T, Ketzer J, Heinrich MC, Grunewald S, Marino-Enriquez A, Trautmann M, Hartmann W, Wardelmann E, Treckmann J, Worm K, Bertram S, Herold T, Schildhaus HU, Glimm H, Stenzinger A, Brors B, Horak P, Hohenberger P, Fröhling S, Fletcher JA, Bauer S. KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy. Mol Cancer Ther. 2019 11; 18(11):1985-1996. PMID: 31308077.
    Citations:    
  9. Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA. Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 Jul; 121(3):281. PMID: 31123346.
    Citations: